Cancer Immunotherapy Insurance Denied? How to Appeal

Insurance companies deny cancer immunotherapy claims regularly, and the patterns are predictable. Checkpoint inhibitors (PD-1/PD-L1 inhibitors like pembrolizumab and nivolumab), CAR-T therapies, and combination immunotherapy regimens represent some of the most contested coverage areas in oncology — and some of the most frequently overturned denials when patients appeal with the right documentation. Understanding the specific legal basis for your appeal is as important as the clinical evidence.

Why Insurers Deny Cancer Immunotherapy Claims

Knowing your denial type is the first step in building an effective appeal.

• "Not medically necessary": The insurer's utilization reviewer determined that immunotherapy does not meet internal clinical criteria, often in direct conflict with your oncologist's assessment and NCCN guidelines.
• "Experimental or investigational": Some checkpoint inhibitors are denied as experimental despite FDA approval and NCCN Category 1 recommendations. This label is factually wrong for FDA-approved therapies used for their approved indications.
• "PD-L1 threshold not met": Some pembrolizumab (Keytruda) approvals require minimum PD-L1 expression (CPS or TPS score). Incomplete biomarker documentation or borderline scores can result in denial.
• "Off-label use not covered": Your oncologist prescribes an immunotherapy agent for a cancer type or biomarker profile beyond the FDA label. Off-label oncology use supported by NCCN guidelines is standard practice and frequently covered under state law.
• "Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization required": Immunotherapy requires extensive prior authorization. Missing or expired PA results in denial regardless of medical necessity.
• "Alternative treatment not exhausted": Insurers may require step therapy — trying a different first-line therapy — even when biomarker profile or clinical factors make immunotherapy the more appropriate initial choice.

How to Appeal an Immunotherapy Denial

Step 1: Request Expedited Review

Cancer does not wait for standard appeal timelines. Under ACA regulations (45 CFR § 147.136) and ERISA (29 CFR § 2560.503-1), you are entitled to an expedited review decision within 72 hours when standard timelines would jeopardize your life or health. Always invoke expedited review for cancer immunotherapy denials — state in writing that treatment delay poses an immediate risk to your health.

Step 2: Request the Insurer's Clinical Policy Bulletin

Obtain the complete claims file including the insurer's clinical policy bulletin applied to your claim. Compare their specific criteria against the NCCN guideline for your cancer type. Discrepancies between the insurer's criteria and NCCN recommendations are the strongest basis for a medical necessity appeal.

Step 3: Engage Your Oncologist for a Comprehensive Letter

Your oncologist should write a detailed letter of medical necessity that: explains your specific cancer, stage, and biomarker profile; states which NCCN guideline recommends the immunotherapy at what evidence category; explains why alternative treatments are not appropriate for your specific case; documents prior treatment lines and their outcomes; and explicitly addresses the insurer's stated denial reason. For off-label use appeals, the letter should also include relevant medical compendium listings (NCCN Drugs and Biologics Compendium, Micromedex DRUGDEX) and peer-reviewed clinical trial data supporting the treatment for your indication.

Step 4: Compile NCCN and Biomarker Evidence

Identify the NCCN guideline for your cancer type and include the specific Category evidence level for your treatment. Attach complete biomarker testing results — PD-L1 IHC (CPS or TPS), MSI/MMR status (which provides tumor-agnostic Keytruda eligibility across all solid tumors), TMB-H status, and cancer-specific markers such as EGFR, ALK, ROS1, BRAF, KRAS, NTRK, RET, and HER2 where applicable. Missing biomarker documentation is the most common reason otherwise valid claims are denied.

Step 5: Request a Peer-to-Peer Review

Your oncologist should request a direct conversation with the insurer's medical director before the appeal is finalized. Peer-to-peer review is particularly effective for immunotherapy denials because the insurer's reviewer may lack oncology expertise. Insist that the reviewing physician be board-certified in oncology with experience in your specific cancer type.

Step 6: Submit the Internal Appeal and Escalate

Submit all supporting evidence with your appeal letter via certified mail and the insurer's online portal. If the internal appeal fails, file immediately for External Independent Review: Complete Guide" class="auto-link">external review requesting an oncology-specialized reviewer, and file a state insurance department complaint. More than 40 states have cancer treatment mandates requiring coverage of NCCN-recommended treatments and off-label drugs listed in recognized compendia.

What to Include in Your Appeal

• Denial letter with reason codes and policy citations
• FDA approval documentation for the specific immunotherapy and your indication
• NCCN guideline excerpt with Category evidence level (Category 1, 2A, or 2B)
• Complete biomarker testing results (PD-L1 IHC, MSI/MMR, TMB, and cancer-specific markers)
• Prior treatment history with dates, regimens, responses, and documented outcomes
• Oncologist's comprehensive letter of medical necessity citing NCCN guidelines and biomarker rationale
• Medical compendium listing for off-label use claims (NCCN Compendium, Micromedex DRUGDEX)
• Peer-reviewed clinical trial publications demonstrating efficacy for your specific indication
• Performance status documentation (ECOG or Karnofsky score)
• Insurer's clinical policy bulletin and your analysis of where it diverges from NCCN standards

Fight Back With ClaimBack

Cancer immunotherapy denials require urgent, evidence-based appeals grounded in NCCN guidelines, FDA approval documentation, complete biomarker data, and your specific clinical history. Time matters in oncology. ClaimBack generates a professional appeal letter in 3 minutes — with the precision cancer appeals demand.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal